Organon & Co. (NYSE:OGN) Receives $8.50 Consensus PT from Analysts

Shares of Organon & Co. (NYSE:OGN) have received a consensus recommendation of “Reduce” from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. Five investment analysts have rated the stock with a sell rating, one has assigned a hold rating and one has issued a strong buy rating on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $8.50.

A number of research analysts have recently issued reports on the company. Zacks Research lowered Organon & Co. from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 29th. Barclays upped their price objective on shares of Organon & Co. from $7.50 to $8.00 and gave the stock an “underweight” rating in a research report on Tuesday, February 24th. Finally, Wall Street Zen downgraded shares of Organon & Co. from a “buy” rating to a “hold” rating in a report on Saturday, January 31st.

Institutional Investors Weigh In On Organon & Co.

Several large investors have recently bought and sold shares of the company. AQR Capital Management LLC lifted its position in shares of Organon & Co. by 105.2% in the fourth quarter. AQR Capital Management LLC now owns 8,570,958 shares of the company’s stock valued at $61,282,000 after acquiring an additional 4,394,814 shares in the last quarter. Vanguard Group Inc. raised its stake in Organon & Co. by 11.3% in the 3rd quarter. Vanguard Group Inc. now owns 35,928,403 shares of the company’s stock valued at $383,715,000 after purchasing an additional 3,650,860 shares during the last quarter. Norges Bank acquired a new position in Organon & Co. in the 2nd quarter valued at $19,778,000. UBS Group AG lifted its holdings in Organon & Co. by 55.2% in the 4th quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock valued at $30,795,000 after purchasing an additional 1,527,492 shares in the last quarter. Finally, Private Management Group Inc. boosted its stake in Organon & Co. by 38.3% during the 4th quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock worth $31,169,000 after purchasing an additional 1,204,979 shares during the last quarter. 77.43% of the stock is currently owned by hedge funds and other institutional investors.

Organon & Co. Stock Performance

NYSE OGN opened at $6.35 on Friday. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of 8.95, a PEG ratio of 0.57 and a beta of 0.67. Organon & Co. has a twelve month low of $5.69 and a twelve month high of $14.70. The company has a current ratio of 1.82, a quick ratio of 1.23 and a debt-to-equity ratio of 11.47. The stock has a 50-day moving average of $7.21 and a 200 day moving average of $7.92.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Thursday, February 12th. The company reported $0.63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.73 by ($0.10). The business had revenue of $1.51 billion for the quarter, compared to analysts’ expectations of $1.52 billion. Organon & Co. had a return on equity of 122.01% and a net margin of 3.01%.The business’s revenue for the quarter was down 5.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.90 EPS. Sell-side analysts anticipate that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 12th. Investors of record on Monday, February 23rd were paid a $0.02 dividend. The ex-dividend date of this dividend was Monday, February 23rd. This represents a $0.08 dividend on an annualized basis and a yield of 1.3%. Organon & Co.’s dividend payout ratio (DPR) is currently 11.27%.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.